It’s Final: No Medicare Coverage For Heart Transplant Rejection Test
This article was originally published in The Gray Sheet
Executive SummaryMedicare will not cover Menssana Research's Heartsbreath heart transplant rejection test, CMS said Dec. 8
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.